patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_567712 | REC_0013201 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.9 | 64 | male | 1 | 12 | 5.6 | 4 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:36:00.292547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147881 | REC_0013202 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 4.5 | 66 | female | 1 | 11 | 4.7 | 1 | pembrolizumab 200 mg q3w | 12.9 | true | MSS | 2026-03-15T05:36:00.292825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634733 | REC_0013203 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 5.6 | 80 | female | 1 | 9 | 9.6 | 2 | pembrolizumab 200 mg q3w | 18.6 | true | MSS | 2026-03-15T05:36:00.293101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338190 | REC_0013204 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 7.9 | 66 | female | 1 | 16 | 5 | 1 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:36:00.293409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325887 | REC_0013205 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 17 | 78 | female | 2 | 18 | 6 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:00.293680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_920881 | REC_0013206 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.8 | 74 | female | 2 | 8 | 4.8 | 5 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:36:00.293937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300240 | REC_0013207 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.2 | 62 | male | 0 | 14 | 4.7 | 3 | osimertinib 80 mg daily | 6.3 | true | MSS | 2026-03-15T05:36:00.294202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111704 | REC_0013208 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.9 | 77 | female | 2 | 26 | 4.7 | 7 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:36:00.294450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478756 | REC_0013209 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.1 | 59 | male | 0 | 16 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 8.4 | false | MSS | 2026-03-15T05:36:00.294839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144219 | REC_0013210 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 7.1 | 56 | female | 1 | 18 | 6.2 | 6 | sotorasib 960 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.295150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635959 | REC_0013211 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10.2 | 61 | male | 1 | 12 | 5.5 | 5 | pembrolizumab 200 mg q3w | 10.6 | false | MSI-H | 2026-03-15T05:36:00.295452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495338 | REC_0013212 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 11.7 | 67 | female | 1 | 13 | 6 | 1 | entrectinib 600 mg daily | 26.5 | true | MSS | 2026-03-15T05:36:00.295721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423250 | REC_0013213 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 18.5 | 65 | female | 0 | 20 | 5.4 | 4 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:00.295994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441062 | REC_0013214 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 22.1 | 66 | male | 1 | 3 | 5.1 | 1 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:36:00.296346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707925 | REC_0013215 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 11.2 | 64 | male | 0 | 18 | 2.8 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:36:00.296656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459007 | REC_0013216 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.4 | 62 | female | 1 | 0 | 6.9 | 5 | osimertinib 80 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:36:00.296977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608332 | REC_0013217 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10 | 72 | female | 3 | 0 | 4.2 | 5 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:00.297266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246288 | REC_0013218 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8 | 65 | female | 0 | 43 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:36:00.297557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782302 | REC_0013219 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.2 | 69 | female | 0 | 15 | 6.5 | 5 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:36:00.297817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933258 | REC_0013220 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 10.3 | 74 | female | 1 | 4 | 5.9 | 0 | pembrolizumab 200 mg q3w | 18.4 | true | MSS | 2026-03-15T05:36:00.298090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137628 | REC_0013221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 21.1 | 60 | male | 0 | 9 | 5.3 | 5 | entrectinib 600 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:36:00.298395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431975 | REC_0013222 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.7 | 74 | female | 1 | 10 | 7.2 | 2 | alectinib 600 mg BID | 20.4 | false | MSS | 2026-03-15T05:36:00.298940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721236 | REC_0013223 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.5 | 66 | male | 1 | 47 | 5.1 | 1 | pembrolizumab 200 mg q3w | 21.3 | true | MSS | 2026-03-15T05:36:00.301475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202502 | REC_0013224 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.8 | 57 | female | 0 | 19 | 6.8 | 2 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.301954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826426 | REC_0013225 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 3.5 | 52 | female | 0 | 34 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:36:00.302327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902491 | REC_0013226 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 25 | 82 | male | 3 | 6 | 7.3 | 5 | osimertinib 80 mg daily | 5.9 | false | MSS | 2026-03-15T05:36:00.302632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893802 | REC_0013227 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.7 | 52 | male | 0 | 54 | 6.5 | 2 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:00.302942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391523 | REC_0013228 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 12.5 | 68 | female | 0 | 19 | 6.1 | 1 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.303255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667478 | REC_0013229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.8 | 80 | female | 3 | 14 | 6.6 | 6 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:36:00.303539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238178 | REC_0013230 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 15.4 | 52 | female | 0 | 16 | 7.3 | 2 | entrectinib 600 mg daily | 18.2 | false | MSS | 2026-03-15T05:36:00.303833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690453 | REC_0013231 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 6.3 | 56 | female | 1 | 16 | 4.2 | 6 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:00.304197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609549 | REC_0013232 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.2 | 49 | male | 0 | 31 | 3.2 | 4 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:36:00.304562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408161 | REC_0013233 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.9 | 73 | male | 2 | 19 | 7.1 | 7 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:36:00.304932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351571 | REC_0013234 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.8 | 75 | female | 2 | 19 | 6.1 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.305266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319783 | REC_0013235 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.3 | 63 | male | 0 | 9 | 4.9 | 2 | alectinib 600 mg BID | 18.8 | false | MSS | 2026-03-15T05:36:00.305786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684184 | REC_0013236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 36 | 13 | 72 | female | 2 | 23 | 6.4 | 1 | alectinib 600 mg BID | 8.3 | false | MSS | 2026-03-15T05:36:00.306134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723452 | REC_0013237 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.6 | 52 | female | 0 | 12 | 5.2 | 6 | osimertinib 80 mg daily | 8.7 | true | MSS | 2026-03-15T05:36:00.306433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277280 | REC_0013238 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 10.2 | 57 | male | 0 | 20 | 7.3 | 1 | alectinib 600 mg BID | 12.5 | true | MSI-H | 2026-03-15T05:36:00.306748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705167 | REC_0013239 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.5 | 78 | female | 1 | 88 | 6.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:00.307064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223367 | REC_0013240 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.8 | 80 | female | 3 | 14 | 6.4 | 4 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:00.307384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448284 | REC_0013241 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 5.7 | 65 | male | 0 | 17 | 4.9 | 1 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:00.307692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199245 | REC_0013242 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.7 | 70 | female | 1 | 13 | 4.2 | 7 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:36:00.307970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379030 | REC_0013243 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.1 | 69 | female | 1 | 27 | 6 | 6 | osimertinib 80 mg daily | 20.2 | true | MSS | 2026-03-15T05:36:00.308343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765450 | REC_0013244 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 16.6 | 68 | female | 0 | 20 | 5 | 0 | sotorasib 960 mg daily | 47.2 | true | MSI-H | 2026-03-15T05:36:00.308683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318799 | REC_0013245 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.7 | 63 | female | 0 | 19 | 6.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.8 | true | MSS | 2026-03-15T05:36:00.308992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585846 | REC_0013246 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 7 | 74 | female | 1 | 15 | 7.1 | 7 | entrectinib 600 mg daily | 21.3 | false | MSS | 2026-03-15T05:36:00.309294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613380 | REC_0013247 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 14.1 | 78 | female | 0 | 11 | 3.6 | 2 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:00.309592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966634 | REC_0013248 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.4 | 64 | female | 1 | 9 | 8.2 | 5 | sotorasib 960 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:36:00.310077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272179 | REC_0013249 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 9.4 | 61 | male | 1 | 22 | 3.8 | 5 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:36:00.310439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106229 | REC_0013250 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.6 | 52 | female | 0 | 44 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:36:00.310722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176543 | REC_0013251 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.9 | 63 | female | 0 | 47 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 18.1 | false | MSS | 2026-03-15T05:36:00.311018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164071 | REC_0013252 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13.4 | 75 | female | 1 | 18 | 5 | 1 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:00.311307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125303 | REC_0013253 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.1 | 76 | female | 1 | 19 | 5.5 | 5 | osimertinib 80 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:36:00.311656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105677 | REC_0013254 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 12.6 | 67 | female | 0 | 9 | 5.9 | 1 | sotorasib 960 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:36:00.312047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478412 | REC_0013255 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 14.5 | 78 | female | 0 | 17 | 6.2 | 1 | pembrolizumab 200 mg q3w | 15.4 | true | MSI-H | 2026-03-15T05:36:00.312461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626592 | REC_0013256 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.6 | 70 | female | 2 | 1 | 5.8 | 7 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:36:00.312796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721625 | REC_0013257 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 9.2 | 67 | male | 0 | 39 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:36:00.313092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603216 | REC_0013258 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.2 | 66 | male | 1 | 19 | 4.8 | 1 | osimertinib 80 mg daily | 29.6 | true | MSI-H | 2026-03-15T05:36:00.313434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684055 | REC_0013259 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.8 | 78 | female | 2 | 45 | 5.6 | 1 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:36:00.313711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109174 | REC_0013260 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.2 | 62 | female | 1 | 35 | 4.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.7 | false | MSS | 2026-03-15T05:36:00.314005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114001 | REC_0013261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 6.7 | 66 | male | 0 | 13 | 5 | 2 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:00.314441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941164 | REC_0013262 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.5 | 81 | female | 2 | 11 | 5.7 | 1 | osimertinib 80 mg daily | 28.1 | false | MSS | 2026-03-15T05:36:00.314769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872333 | REC_0013263 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 10.9 | 71 | female | 1 | 17 | 4.2 | 4 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:36:00.315113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930008 | REC_0013264 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.1 | 76 | male | 2 | 14 | 6.8 | 1 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:36:00.315468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353685 | REC_0013265 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 16.8 | 70 | female | 2 | 11 | 6.7 | 6 | alectinib 600 mg BID | 13.1 | true | MSI-H | 2026-03-15T05:36:00.315840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208971 | REC_0013266 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 7.4 | 71 | female | 2 | 11 | 6.1 | 5 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:00.316356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916823 | REC_0013267 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.5 | 75 | male | 1 | 26 | 6 | 2 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:00.316751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598925 | REC_0013268 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.4 | 72 | female | 1 | 21 | 6 | 8 | osimertinib 80 mg daily | 5.3 | true | MSS | 2026-03-15T05:36:00.317081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742109 | REC_0013269 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.4 | 59 | male | 0 | 18 | 4.9 | 7 | pembrolizumab 200 mg q3w | 5.1 | false | MSS | 2026-03-15T05:36:00.317403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869506 | REC_0013270 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 7.7 | 73 | female | 2 | 25 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:36:00.317734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847343 | REC_0013271 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.6 | 64 | female | 0 | 0 | 7.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:36:00.318095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867617 | REC_0013272 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 17.6 | 63 | male | 0 | 8 | 6.8 | 7 | alectinib 600 mg BID | 11.5 | true | MSI-H | 2026-03-15T05:36:00.318431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662843 | REC_0013273 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 5.3 | 73 | male | 1 | 21 | 4.8 | 6 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:00.318753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916421 | REC_0013274 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 6.5 | 77 | male | 0 | 12 | 6.7 | 2 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.319270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787556 | REC_0013275 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.5 | 77 | female | 1 | 67 | 7.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:36:00.319700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121720 | REC_0013276 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 16.2 | 57 | female | 0 | 15 | 6.8 | 7 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:36:00.324272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511370 | REC_0013277 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.8 | 65 | male | 0 | 52 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:36:00.324820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149881 | REC_0013278 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.9 | 70 | female | 1 | 17 | 3.4 | 5 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:36:00.325168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539913 | REC_0013279 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12.4 | 58 | female | 0 | 11 | 4.2 | 7 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:36:00.325485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456663 | REC_0013280 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 7.7 | 63 | male | 1 | 15 | 4.9 | 5 | sotorasib 960 mg daily | 5.7 | false | MSS | 2026-03-15T05:36:00.325771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827246 | REC_0013281 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.3 | 65 | male | 0 | 22 | 6.2 | 3 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:36:00.326075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353729 | REC_0013282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.3 | 74 | female | 2 | 12 | 3.8 | 4 | alectinib 600 mg BID | 9.4 | true | MSI-H | 2026-03-15T05:36:00.326406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511642 | REC_0013283 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 37 | 8.3 | 72 | female | 1 | 0 | 5 | 4 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:00.326708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339478 | REC_0013284 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11 | 79 | female | 2 | 2 | 7.2 | 1 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:36:00.327008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396520 | REC_0013285 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 19 | 58 | male | 1 | 8 | 4.7 | 2 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:36:00.327305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610795 | REC_0013286 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.2 | 66 | male | 0 | 17 | 4.3 | 4 | alectinib 600 mg BID | 6.5 | true | MSI-H | 2026-03-15T05:36:00.327591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626176 | REC_0013287 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 6.4 | 77 | female | 1 | 4 | 5.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 67.4 | false | MSS | 2026-03-15T05:36:00.330260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270099 | REC_0013288 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 7.3 | 76 | female | 1 | 16 | 5.9 | 1 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:36:00.330782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590304 | REC_0013289 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.4 | 77 | male | 2 | 18 | 6.3 | 6 | alectinib 600 mg BID | 16.6 | true | MSS | 2026-03-15T05:36:00.331170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683902 | REC_0013290 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.2 | 62 | female | 1 | 56 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.1 | false | MSS | 2026-03-15T05:36:00.331534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447248 | REC_0013291 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.6 | 76 | female | 2 | 44 | 2.3 | 5 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:36:00.331868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441851 | REC_0013292 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 3.6 | 71 | female | 3 | 44 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 23 | true | MSS | 2026-03-15T05:36:00.332913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454809 | REC_0013293 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.7 | 67 | female | 0 | 54 | 7.1 | 5 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:36:00.333385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966789 | REC_0013294 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 16.1 | 56 | male | 1 | 16 | 5.5 | 2 | sotorasib 960 mg daily | 19.1 | true | MSS | 2026-03-15T05:36:00.333739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868136 | REC_0013295 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.7 | 65 | male | 0 | 9 | 5.8 | 3 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:36:00.334065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498382 | REC_0013296 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.9 | 60 | female | 0 | 12 | 4.7 | 6 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:00.334377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247851 | REC_0013297 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.4 | 61 | male | 1 | 19 | 7.6 | 2 | osimertinib 80 mg daily | 4.3 | true | MSS | 2026-03-15T05:36:00.334796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103201 | REC_0013298 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 11.3 | 80 | female | 3 | 14 | 7.1 | 1 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:36:00.335152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706274 | REC_0013299 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16 | 70 | female | 2 | 22 | 5.4 | 1 | osimertinib 80 mg daily | 20.6 | true | MSS | 2026-03-15T05:36:00.335500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814417 | REC_0013300 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.7 | 76 | female | 1 | 8 | 6.2 | 1 | entrectinib 600 mg daily | 17.7 | true | MSS | 2026-03-15T05:36:00.336041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.